Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The group used a randomized controlled trial to conduct a post-marketing re-evaluation study
of Wangbi granules. The study was conducted to observe the degree of clinical remission in
rheumatoid arthritis patients with low disease activity after standard methotrexate and
tofacitinib citrate treatment, using a combination of Chinese and Western medicine treatment
with Wangbi granules. The study aims to provide evidence-based medical evidence to improve
the clinical efficacy of rheumatoid arthritis, enhance the depth of remission, and improve
the diagnosis and treatment of rheumatoid arthritis.